Skip to search formSkip to main contentSkip to account menu

Ganglioside GM1 Ab:PrThr:Pt:Ser:Ord:IF

Known as: Ganglioside GM1 Antibody:Presence or Threshold:Point in time:Serum:Ordinal:Immune Fluorescence, Ganglioside GM1 , Ac:Présence-Seuil:Temps ponctuel:Sérum:Ordinal:Immunofluorescence, S--monosialoganglioside GM1, Ig; ; IF 
National Institutes of Health

Related topics

Related topics

6 relations
AntibodiesGanglioside GM1GangliosidesIMMUNE FLUORESCENCE

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Abstract 15482: Medin Amyloid Protein-Induced Human Leptomeningeal Arteriole Endothelial Dysfunction and Pro-Inflammatory Signaling are Reversed by Monosialoganglioside Nanoliposomes
Background: Medin is a 50 amino acid peptide that forms amyloid deposits in the vasculature. It is the most common human amyloid… 
2013
2013
[Determination of monosialogangliosides in sea cucumbers and sea urchins using liquid chromatography-tandem mass spectrometry].
An approach based on liquid chromatography-tandem mass spectrometry was developed for the quantification of monosialogangliosides… 
2008
2008
The Protective Effect of Monosialoganglioside-GM_1 on Severe Traumatic Brain Injury
Aim :To study the protective effect of monosialoganglioside-GM1 on people inflicted of severe traumatic brain injury(STBI… 
2007
2007
Avaliação dos efeitos da administração do gangliosideo GM1 na modulação do diabetes mellitus autoimune e expressão de citocinas, Nerve Growth Factor e seu receptor TrkA em camundongos NOD (non obese…
A linhagem de camundongos NOD (non obese diabetic) desenvolve espontaneamente diabetes mellitus tipo 1 (DM-1) com marcante… 
Highly Cited
2003
Highly Cited
2003
Formation of a membrane-active form of amyloid beta-protein in raft-like model membranes.
2003
2003
Biochemical and molecular characterization of mutant hexosaminidase A in a Turkish family
Abstract Background : Tay‐Sachs disease is a form of monosialoganglioside triaose (GM2) gangliosidosis that results from the… 
Highly Cited
1994
Highly Cited
1994
Early Treatment of Stroke With Monosialoganglioside GM‐1: Efficacy and Safety Results of the Early Stroke Trial
Background and Purpose The Early Stroke Trial (EST) is a randomized, double-blind, placebo-controlled trial to assess the effect… 
1993
1993
Use of monosialoganglioside GMl or by N-dichloro-acetyl-lyso-GMl for the prevention or reversal of the induced by long-term treatment with L-DOPA in the treatment of Parkinson's disease, neuronal…
1990
1990
Augmentation of mouse natural killer (NK) activity by GM-1/P, a processed form of monosialoganglioside GM-1.
We describe the immunomodulatory activity of GM-1/P a processed form of GM-1 (monosialoganglioside) extracted from ox brain… 
1990
1990
A pilot study with monosialoganglioside GM1 on acute cerebral ischemia.
Reported here are the results of an open controlled study on the use of GM1 in cases of ischemic strokes in its acute phase. A… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)